Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01943825
Recruitment Status : Completed
First Posted : September 17, 2013
Results First Posted : February 5, 2020
Last Update Posted : February 5, 2020
Sponsor:
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )

Brief Summary:

The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine.

Primary Objectives:

  • To describe and compare the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose.
  • To describe the persistence of the humoral immune response to each of the 4 parental dengue virus serotypes 6 after CYD dengue vaccine Dose 3, irrespective of whether or not JE vaccine had been previously administered.

Secondary Objectives:

  • To describe the safety profile after each injection of CYD dengue vaccine.
  • To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose when administered with or after JE virus vaccine in Groups 3 and 4.
  • To describe the persistence of the humoral immune response to each of the 4 parental dengue virus serotypes at 6 months post-dose 3 in all four groups and at 12 months post-dose 3 in Groups 1 and 3 with the compressed schedule.
  • To determine the level of viremia on Day (D)0, D3, D5, D7 and D14 following each CYD vaccine dose administered in Groups 1-4.
  • To describe the JE humoral immune response at baseline and 28 days after each injection of CYD dengue vaccine in Groups 3 and 4.

Condition or disease Intervention/treatment Phase
Dengue Dengue Fever Dengue Hemorrhagic Fever Biological: CYD Dengue Vaccine Biological: Japanese Encephalitis Vaccine Phase 2

Detailed Description:
Study participants were randomly assigned to one of the four groups to receive assigned study vaccine and were evaluated for neutralizing antibody titers; markers of cell-mediated immunity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine
Actual Study Start Date : November 5, 2013
Actual Primary Completion Date : November 25, 2015
Actual Study Completion Date : November 25, 2015


Arm Intervention/treatment
Experimental: CYD Dengue Vaccine: Group 1
Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
Biological: CYD Dengue Vaccine
0.5 mL, Subcutaneous

Experimental: CYD Dengue Vaccine: Group 2
Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
Biological: CYD Dengue Vaccine
0.5 mL, Subcutaneous

Experimental: CYD Dengue and JE Vaccine: Group 3
Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
Biological: CYD Dengue Vaccine
0.5 mL, Subcutaneous

Biological: Japanese Encephalitis Vaccine
0.5 mL, Intramuscular
Other Name: IXIARO Japanese Encephalitis Vaccine

Experimental: CYD Dengue and JE Vaccine: Group 4
Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
Biological: CYD Dengue Vaccine
0.5 mL, Subcutaneous

Biological: Japanese Encephalitis Vaccine
0.5 mL, Intramuscular
Other Name: IXIARO Japanese Encephalitis Vaccine




Primary Outcome Measures :
  1. Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains [ Time Frame: Pre-injection 1, 2 and 3; 28 days post-injection 1, 2 and 3; and 6 months post-injection 3 ]
    GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by plaque reduction neutralization test (PRNT). The lower limit of quantitation (LLOQ) of the assay was a titer of 10 (1/dilution).

  2. Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains [ Time Frame: Pre-injection 1, 2 and 3; 28 days post-injection 1, 2 and 3; and 6 months post-injection 3 ]
    Antibody titers against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT.


Secondary Outcome Measures :
  1. Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains in Participants Who Received Japanese Encephalitis Vaccine - Groups 3 and 4 [ Time Frame: Pre-injection 1, 2 and 3, and 28 days post-injection 1, 2 and 3 ]
    GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT. The LLOQ of the assay was a titer of 10 (1/dilution).

  2. Geometric Means Titers of Antibodies Against Each Dengue Virus Serotype Strains [ Time Frame: 6 months and 12 months post-injection 3 ]
    GMTs of antibodies against each dengue virus serotype (parental strains 1, 2, 3 and 4) were measured by PRNT.

  3. Number of Participants With Detectable Non Serotype-Specific Vaccine Viremia [ Time Frame: 3, 5, 7 and 14 days post-injection 1, 2 and 3 ]
    Viremia was determined by reverse transcriptase (RT) polymerase chain reaction (PCR) using primer/probes specific to a non serotype-specific part of the dengue vaccine.

  4. Number of Participants With Detectable Serotype-Specific Vaccine Viremia [ Time Frame: 3, 5, 7 and 14 days post-injection 1; 3 and 14 days post-injection 2 and 7 days post-injection 3 ]
    Viremia was determined by RT PCR using primer/probes specific to each dengue vaccine serotypes.

  5. Geometric Means Titers of Antibodies Against Japanese Encephalitis - Groups 3 and 4 [ Time Frame: Pre-injection 1, and 28 days post-injection 1, 2 and 3 ]
    GMTs of antibodies against JE were measured by JE micro neutralization assay. The LLOQ of the assay was a titer of 10 (1/dilution).

  6. Number of Participants With Solicited Injection Site Reactions [ Time Frame: Within 7 days after any CYD dengue vaccine and/or JE vaccine ]
    A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the electronic case report form (eCRF) and considered as related to vaccination. Solicited injection site reactions: pain, erythema, and swelling.

  7. Number of Participants With Solicited Systemic Reactions [ Time Frame: Within 14 days after any CYD dengue vaccine and/or JE vaccine ]
    A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions: fever, headache, malaise, myalgia, and asthenia.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged greater than or equal to (>=)18 to less than or equal to (<=) 45 years on the day of inclusion.
  • Informed consent form had been signed and dated.
  • Able to attend all scheduled visits and complied with all trial procedures.
  • Participant was in good health, based on medical history and physical examination.

Exclusion Criteria:

  • Participant was pregnant, or lactating, or of childbearing potential (were considered of non-childbearing potential, a female had to be post- menopausal for at least 1 year, surgically sterile, or used an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination).
  • Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt or planned receipt of any vaccine, outside the study protocol in the 4 weeks preceded or followed trial vaccinations. (If influenza activity warranted vaccination of healthy young adults, influenza vaccination was encouraged and did not lead to study exclusion).
  • Any history of FV vaccination, or planned FV vaccination during the trial period.
  • Previous residence (greater than [>]12 months) in, or travel in the last 30 days to dengue endemic regions.
  • Receipt of immune globulins, blood or blood-derived products in the 3 months prior to first vaccination or planned use during the study period.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceded 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic hypersensitivity to any of the vaccine components (including protamine sulfate), or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances, including dry natural latex.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Excessive alcohol consumption or drug addiction.
  • Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.
  • Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator.
  • Temporary Exclusion Criteria: Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature >= 38.0 degree Celsius [>= 100.4 degree fahrenheit]). A prospective participant was not included in the study until the condition had resolved or the febrile event had subsided. If the delay for the febrile illness exceeded the window between screening and vaccination, or if deemed necessary by the Investigator, a prospective participant might be re-screened once the fever had resolved.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01943825


Locations
Layout table for location information
United States, New York
Syracuse, New York, United States, 13210
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
United States Department of Defense
Investigators
Layout table for investigator information
Study Director: Medical Director Sanofi Pasteur SA
Layout table for additonal information
Responsible Party: Sanofi Pasteur, a Sanofi Company
ClinicalTrials.gov Identifier: NCT01943825    
Other Study ID Numbers: CYD56
U1111-1143-8391 ( Other Identifier: WHO )
First Posted: September 17, 2013    Key Record Dates
Results First Posted: February 5, 2020
Last Update Posted: February 5, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to participant level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Participant level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/
Keywords provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):
Dengue
Dengue fever
CYD dengue vaccine
IXIARO JE vaccine
Flavivirus
Additional relevant MeSH terms:
Layout table for MeSH terms
Dengue
Hemorrhagic Fevers, Viral
Severe Dengue
Fever
Body Temperature Changes
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs